Drawing for BORYUNG

USPTO serial 87540250

BORYUNG

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
PERRY, KIMBERLY B
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with BORYUNG?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Daniel I. Schloss

DANIEL I. SCHLOSS GREENBERG TRAURIG, LLP200 PARK AVE., 38TH FL.NEW YORK, NY 10166UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals for hypertension prevention; Pharmaceutical preparations acting on nervous system; medicines for sensory organs, namely, pharmaceutical preparations for the treatment and prevention of disorders of sensory organs; allergy medications; pharmaceutical preparations for the treatment of cardiovascular system related diseases and disorders; pharmaceutical preparations for treating respiratory organs diseases; pharmaceutical preparations acting on digestive organs for treating digestive diseases; pharmaceutical preparations for urogenital organs for treating urogenital diseases; vitamin preparations; pharmaceutical preparations for endocrine systems for the treatment of endocrine-related diseases and disorders; pharmaceutical preparations for tumor treatment; antibiotic preparations for medical purposes; biological preparations for medical purposes for the treatment of diseases and disorders of the sensory organs, cardiovascular system, digestive organs, urogenital organs, and endocrine system, and for the treatment of allergies and tumors; antifungal preparations for medical purposes; pharmaceutical preparations for cell therapy; Pharmaceutical preparations for the treatment of leukemia; Nutraceuticals for use as dietary supplementsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Sep 3, 2019MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Sep 2, 2019ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 29, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jan 25, 2019EX2GSOU EXTENSION 2 GRANTED—
Jan 25, 2019EXT2SOU EXTENSION 2 FILED—
Jan 25, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Aug 1, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jul 30, 2018EX1GSOU EXTENSION 1 GRANTED—
Jul 30, 2018EXT1SOU EXTENSION 1 FILED—
Jul 30, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 30, 2018NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Dec 5, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Dec 5, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 15, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 31, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 23, 2017DOCKASSIGNED TO EXAMINER—
Jul 29, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 27, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance